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Summary. Hormone replacement therapy (HRT) mcreases
the risk of venous thrombosis We mvestigated whether this
risk is affected by carriership of hereditary prothrombotic
abnormahties Therefore, we determmed the two most
common prothrombotic mutdtions, factor V Leiden and
prothrombin 20210A m women who participated m a
case-control study on venous thrombosis Relative nsks
were expressed äs odds ratios (OR) with 95% confidence
mtervals (CI95) Among 77 women dged 45-64 years with
d first venous thrombosis, 51% were receiving HRT at the
time of thrombosis, compared with 24% of control women
(OR = 33, CI95 l 8-5 8) Among the patients, 23% had a
prothrombotic defect, versus 7% among the control women
(OR = 38, CI95 l 7-8 5) Women who had factor V Leiden
and used HRT had a 15-fold mcreased risk (OR = 155,
CI95 3 1-77), which exceeded the expected jomt odds ratio
of 6 l (under an additive model) We conclude that the
thrombotic risk of HRT may particularly affect women with
prothrombotic mutations Efforts to avoid HRT m women
with mcreased risk of thrombosis are advisable
Keywords: venous thrombosis, oestrogens, hormone
replacement therapy, factor V Leiden, prothrombin
20210A
Several recent studies have demonstrated that the use of
hormone replacement therdpy (HRT) is dssocidted with an
mcreased risk of venous thrombosis, i e deep-vem throm-
bosis and pulmonary embolism (Daly et al, 1996, Grodstem
et al, 1996; Jick et al, 1996, Grady et al, 2000) The reports
pomted to a two- to fourfold mcreased risk, which is not
very different from the relative risk conferred by oral
contraceptives (Vessey & Doll, 1968, Stadel, 1981) This
was surpnsmg given the low oestrogen and progestogen
doses m HRT As the risk of thrombosis, in absolute terms, is
highly dependent on age, these data imply that HRT might
lead to a considerable number of excess cases of deep-vem
thrombosis among post-menopausal women
To prevent thrombosis äs a result of the use of HRT, it is
necessary to identify women at mcreased risk Previously,
we have demonstrated a synergistic effect between the use
of oral contraceptives and the most common prothrombotic
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defect, factor V Leiden (Vandenbroucke et al, 1994)
Therefore, we hypothesized that women with hereditary
thrombophilia would be at high risk of thrombosis when
usmg HRT
We remvestigated participants m the Oxford hospital-
based case-control study (Daly et al, 1996) of HRT and the
occurrence of venous thrombosis for the presence of
prothrombotic mutations, which we hmited to the two
most prevalent abnormahties, factor V Leiden and
prothrombin 20210A, each of which is found in several
per cent of the general Caucasian population (Rees et al,
1995, Rosendaal ei al, 1998) We have reported previously
on prothrombotic phenotypes in this group (Löwe et al,
2000)
PATIENTS AND METHODS
The original case-control study included 103 women aged
45-64 years admitted to hospital between April 1990 and
December 1994 in the Oxford Regional Health Authonty
area, with a mam diagnosis of a first episode of deep-vem
thrombosis or pulmonary embolism (Daly et al, 1996) For
companson, control women were recruited from women
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admitted to hospital for diagnoses unrelated to thrombosis
and HRT. Up to two control women were chosen per case,
matched by 5-year age group, district of admission and date
of hospitalization. Women with a history of stroke, myo-
cardial infarction, malignancies or who had been pregnant,
had undergone surgery or had been immobilized in the
6 weeks before admission were excluded from the case and
control groups. Results have been published previously
(Daly et al, 1996).
For the follow-up study in 1995-96 (Löwe et al, 2000),
all surviving women were invited to take part in a study of
thrombotic phenotypes and genotypes. The study was
approved by local research ethics committees. Venous
blood was obtained from the antecubital vein and antico-
agulated with EDTA. DNA was extracted by salting out
procedures. DNA analysis for factor V Leiden (factor V
G1691A) and prothrombin mutation (G20210A) were
performed by Standard polymerase chain reaction (PCR)
procedures.
We calculated the relative risk associated with HRT and
with carriership of a prothrombotic mutation by exposure
odds ratios. These indicate the risk of thrombosis in those
with the risk factor relative to those without the risk factor.
Ninety-flve per cent confidence intervals (CI95) were
estimated according to the method of Woolf (1955) or
derived from the logistic regression model. When numbers
were small, exact confidence intervals were computed
(Mehta, 1994) using EPI INFO 6 [Centers for Disease Control
(CDC), Atlanta, G A, USA]. The original matching is
accounted for in our analyses by adjustment for age and
district of admission. In some analyses, we grouped factor V
Leiden and prothrombin 20210A carriers together. Where
numbers allowed, we presented separate risk estimates for
both genetic variants. The effect of the combination of
prothrombotic mutations was investigated by comparing
those with either risk factor and those with both risk factors
with those with neither.
RESULTS
DNA was obtained from 77 of the 80 eligible consenting
women with venous thrombosis and 163 of the 171 eligible
consenting control women. Their general characteristics are
shown in Table I.
Among the patients, 51% used HRT at the time of the
thrombosis, compared with 24% of control women, which
indicated a more than threefold increased risk (OR = 3-3,
CI95 1-8-5-8). A prothrombotic mutation (factor V Leiden
or prothrombin 2021OA) was present in 23% of women
with thrombosis (all heterozygous) versus 7% among
controls (all heterozygous), with a nearly fourfold
increased risk (OR = 3-8, CI95 1-7-8-5). Adjustment for
the stratification factors, age and area of admission, did
not affect these risk estimates. Factor V Leiden was
associated with a fourfold increased risk (OR = 4-0, CI95
1-6-10-2) and prothrombin 20210A with a twofold
increased risk (OR = 2-2, CI95 0-2-30-3). Of 18 throm-
bosis cases with a prothrombotic mutation, eight were
hormone users at the time of thrombosis. Of these eight





Mean age, years (ränge) 54 (45-64) 54 (45-64)
Oral anticoagulant therapy (%) 11* (14) 0(0)
HRT
At thrombosisf (%) 39 (51) 39 (24)
At venepuncture (%) 18 (23) 52 (32)
Factor V Leiden
GG (%) 61 (79) 153 (94)
AG (%) 16 (21) 10 (6)
Prothrombin 20210
GG (%) 75 (97) 161 (99)
AG (%) 2 (3) 2 (1)
"These patients were excluded from previous analyses of hae-
mostatic factors (Löwe et al, 2000).
-fOr at a similar index date for the controls.
Table II. Factor V Leiden and HRT.













women, flve (62%) were in their flrst year of hormone use,
compared with 32% of all cases using HRT (and 23% of
controls) (Daly et al, 1996).
Subsequently, we investigated the joint effect of pro-
thrombotic mutations and HRT on the risk of venous
thrombosis. Whereas HRT and prothrombotic mutations
separately each increased thrombotic risk about fourfold,
the combination led to an ll-fold increased risk (OR =11,
CI95 2-7-44), which exceeded the expected odds ratio of 7-1
if the risks had been additive. Only four women carried the
prothrombin variant, none of whom also used HRT. Given
this low number of carriers, separate risk estimates for this
variant were not meaningful. Table II shows the separate
and joint effects of factor V Leiden and HRT. The combi-
nation of factor V Leiden and hormone treatment increased
the risk of thrombosis 15-fold (OR = 15-5, CI95 3-1-76-7),
clearly exceeding the sum of the separate effects of the two
risk factors (expected joint odds ratio 6-1).
DISCUSSION
This reinvestigation of participants in a case-control study
of idiopathic venous thrombosis demonstrated that HRT
and prothrombotic mutations (factor V Leiden, prothrombin
2 0210A) increase the risk of venous thrombosis in women
aged 45-64 years.
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The highest nsk of thrombosis was found in women who
used HRT and carried the factor V Leiden mutation (15-
fold) The mcreased nsk of venous thrombosis m HRT users
who are carners of the factor V Leiden mutation is
consistent with our recent report of an mcreased nsk in
HRT users with activated protem C (APC) resistance, the
thrombotic phenotype associated with this mutation (Löwe
et al, 2000) A high thrombotic nsk for the combmation of
hormone use and factor V Leiden was analogous to the
synergistic effect we reported previously for oral contra-
ceptive use and factor V Leiden (Vandenbroucke et al,
1994) Furthermore, the new data suggest that the associ-
ation of the APC-resistant phenotype with mcreased nsk of
venous thrombosis, äs reported previously (Löwe et al,
2000), results from the pre-existmg genetic mutation and
not from acquired APC resistance attributable to HRT or
venous thrombosis A second analogy with thrombosis
resultmg from oral contraceptive use was the association
with recent use (Bloemenkamp et al, 2000) for oral
contraceptives, we reported a higher nsk during the flrst
year of use than for prolonged use, which was most
pronounced for women with inhented coagulation defects
(Bloemenkamp et al, 2000) In the original case-control
study, the nsk was mcreased 3 1-fold during the first year of
hormone replacement and 2 1-fold during subsequent years
(both relative to non-users) (Daly et al, 1996) The prepon-
derance of first-year users among cases with a prothrom-
botic mutation (63%) also suggests a higher risk for these
women during the flrst year of HRT use, although the
number of women was too small to reach defimte conclu-
sions.
The 15-fold mcreased risk of the combmation of HRT
and factor V Leiden exceeds the expected jomt risk based
on the separate effects, which would be a sixfold mcreased
risk (under an additive model) Because of the limited
number of women in the group with both nsk factors,
however, the conftdence mterval around this estimate was
wide
These results raise a safety issue, in particular the
question of how to rmmmize the use of HRT among women
with a high risk of thrombosis This question is of
considerable importance, m particular because recently
the long-term arterial beneflts of HRT have become doubt-
ful, with randomized tnals failmg to demonstrate a benefit
(Hulley et al, 1998) In makmg a decision to prescnbe HRT,
risk mmimization strategies may be considered that include
detailed history taking (personal and farmly history of
thrombosis) or screening for prothrombotic mutations Such
pohcies might assist women and clmicians to make rational
and mformed decisions. Even though a case-control study
only allows the calculation of relative risks, and not of
absolute nsks, we can make some estimates about the effect
of selective prescription The overall incidence of venous
thrombosis is one or two per 1000 per year and has a steep
age gradient (Rosendaal, 1997). Therefore, m absolute
terms, a relative risk of 4 associated with HRT has a much
larger impact on women's health than the same relative nsk
for oral contraceptives, äs m women of reproductive age,
the incidence is about one per 10000, whereas m
post-menopausal women, it is over one per 1000 per year
and increases with more advanced age (Anderson et al,
1991, Nordstrom et al, 1992, Kniffin et al, 1994, Silverstem
et al, 1998, Löwe et al, 2000, Oger, 2000)
With a baselme incidence of one to four per 1000 per
year in women aged 45-79 years, screening for factor V
Leiden with a prevalence of 5%, and subsequent with-
holdmg of HRT in those tested positive, would prevent 5-25
thrombotic events annually per 10 000 women screened
With 5 or 10 years of use, screening could well be
worthwhile The effects of screening m preventmg throm-
bosis are hkely to be highest m older women On the other
hand, it may prevent more thrombotic events and be more
cost-effective to withhold HRT in women with other risk
factors for venous thrombosis (such äs gross obesity), or m
women with a farmly history of venous thrombosis
In conclusion, the thrombotic risk of HRT may par-
ticularly affect women with prothrombotic mutations, spe-
ciflcally factor V Leiden Given the high prevalence of this
mutation, efforts to mimmize prescription of HRT to women
with an mcreased risk should be undertaken. The results
presented here are based on a relatively small study and
urgently need to be confirmed m a larger study, such äs the
on-going tnals of HRT
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